Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Product/Service, Trade Show

Ayala Pharmaceuticals Announces Presentation at the European Society for Medical Oncology (ESMO)


Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to developing targeted cancer therapies for people living with genetically defined cancers, today announced that a poster will be presented at the European Society for Medical Oncology (ESMO), being held in Barcelona, Spain from September 27 to October 1, 2019.

Presentation information is as follows:

Title: ACCURACY a phase (P) 2 trial of AL101, a pan-Notch inhibitor, in recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) patients (pts) with Notch activating mutations (Notchact mut): preliminary safety and efficacy data 
Session Title: Poster Display Session 
Session Date and Time: Monday, September 30, 2019 at 12:00pm to 1:00pm CET 
Presentation Number: 1148P 
Location: Poster Area (Hall 4) 
Presenter: Alan L. Ho, M.D., Ph.D., Memorial Sloan Kettering Cancer Center

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing targeted cancer therapies for people living with genetically defined cancers. Ayala is broadly developing its product candidates, AL101 and AL102, best-in-class gamma secretase inhibitors, with clinical and preclinical studies underway in both solid tumors (AL101) and hematologic malignancies (AL102). Ayala's lead product candidate, AL101, is currently in phase 2 for adenoid cystic carcinoma patients with tumor bearing Notch activating mutations (ACCURACY). For more information, visit www.ayalapharma.com


These press releases may also interest you

at 02:00
Ceridian , a global leader in human capital management (HCM), today announced Henkel, a global industrial and consumer goods leader, has selected Ceridian and the Dayforce platform to deliver its payroll and workforce management needs, with...

at 01:05
Data Gumbo, provider of GumboNettm ? the massively interconnected industrial smart contract network secured and powered by blockchain ? today announced that it enables real-time operational expenses (OPEX) visibility for energy operators and service...

at 01:00
In response to the situation lots of trade fairs have been cancelled due to COVID-19, JETRO Kyoto will hold a virtual exhibition with overseas buyers to sell products from Kyoto. JETRO Kyoto has just opened a special virtual exhibition site. 3D...

at 01:00
Sartorius Stedim Biotech, a leading partner of the biopharma industry, recorded exceptionally strong growth in 2020 that was driven by strong organic development, several acquisitions and additional momentum from business related to the coronavirus...

at 01:00
The life science group Sartorius recorded high growth according to preliminary figures in 2020 due to strong organic development, several acquisitions and the additional momentum from business related to the coronavirus pandemic. The Group closed the...

at 00:55
January 2021, Thousand Oaks Biopharmaceuticals Group ("Thousand Oaks") announced that it had signed a Joint Venture agreement with WSG Group in Busan, Korea, to establish a bioprocess solution joint venture (including cell culture media, single-use...



News published on 19 september 2019 at 16:05 and distributed by: